Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 6.

Hirschmann, A; Lupatsch, J E; Schwenkglenks, M; Panje, C M; Matter-Walstra, K; Espeli, V; Dedes, K J; Siano, M (2018). Cost-effectiveness of nivolumab in the treatment of head and neck cancer. Oral Oncology, 87:104-110.

Matter-Walstra, K; Schwenkglenks, Matthias; Dedes, K J (2017). Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting. Breast Cancer Research and Treatment, 163(3):635.

Matter-Walstra, K; Braun, R; Kolb, C; Ademi, Z; Dummer, R; Pestalozzi, B C; Schwenkglenks, M (2015). A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting. British Journal of Dermatology, 173(6):1462-1470.

Joerger, M; Matter-Walstra, K; Früh, M; Kühnel, U; Szucs, T; Pestalozzi, B; Schwenkglenks, M (2011). Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Annals of Oncology, 22(3):567-574.

Matter-Walstra, K; Schwenkglenks, M; Szucs, T D; Pestalozzi, B (2011). How to get involved in a health economic analysis: an introduction for clinical researchers. Schweizer Krebs-Bulletin = Bulletin Suisse du Cancer, 31(2):144-146.

Dedes, K J; Matter-Walstra, K; Schwenkglenks, M; Pestalozzi, B C; Fink, D; Brauchli, P; Szucs, T D (2009). Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. European Journal of Cancer, 45(8):1397-1406.

This list was generated on Sun Apr 21 12:22:35 2019 CEST.